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Abstract
Background: Studies centered on the detection of cognitive impairment and its relationship to cardiovascular risk
factors in elderly people have gained special relevance in recent years. Knowledge of the cardiovascular risk factors
that may be associated to cognitive impairment could be very useful for introducing treatments in early stages -
thereby possibly contributing to improve patient quality of life.
The present study explores cognitive performance in people over 65 years of age in Salamanca (Spain), with special
emphasis on the identification of early symptoms of cognitive impairment, with the purpose of detecting mild
cognitive impairment and of studying the relationships between this clinical situation and cardiovascular risk factors.
Methods/Design: A longitudinal study is contemplated. The reference population will consist of 420 people over
65 years of age enrolled through randomized sampling stratified by healthcare area, and who previously
participated in another study. Measurement: a) Sociodemographic variables; b) Cardiovascular risk factors; c)
Comorbidity; d) Functional level for daily life activities; and e) Study of higher cognitive functions based on a
neuropsychological battery especially adapted to the evaluation of elderly people.
Discussion: We hope that this study will afford objective information on the representative prevalence of cognitive
impairment in the population over 65 years of age in Salamanca. We also hope to obtain data on the relationship
between cognitive impairment and cardiovascular risk factors in this specific population group. Based on the
results obtained, we also will be able to establish the usefulness of some of the screening tests applied during the
study, such as the Mini-Mental State Examination and the 7 Minute Screen test.
Trial registration: ClinicalTrials.gov: NCT01327196
Background
The study of cognitive impairment in elderly people
presently constitutes an important challenge, considering
that the population life expectancy has increased signifi-
cantly in the last decades. With advancing age, and
particularly after 60 years of age, the prevalence of cogni-
tive impairment increases almost exponentially, and
represents one of the main causes of disability among the
elderly[1-5]. In the European Union it has been estimated
that over 5 million inhabitants suffered dementia in the
year 2005 (1.14-1.27% of the population), with a total of
583,208 registered cases in Spain that year [6]. In the
region of Castilla y León, the estimated prevalence of
dementia is 6.4% in people aged 65 years and older -
representing about 43,500 individuals. This situation now
constitutes an important clinical, healthcare and socioe-
conomic problem, in view of the sanitary and care
requirements involved, the important family impact, and
the scarcity of effective therapeutic resources. Few studies
on the economical cost of dementia have been conducted
in our setting, though the estimated cost exceeds 9000
euros per patient and year, considering only the direct
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etc. If the indirect costs associated with the disease are
also taken into account, then the figure per patient
reaches 19,000 euros per year. During the year 2004, the
cost totaled over 8200 million euros in Spain alone [7].
Although cognitive impairment is the most relevant
symptom, dementia is usually also associated to different
behavioral, psychological and functional manifestations
that affect the functional and executive capacities of the
individual - interfering with normal family, social and
occupational activities, and lessening the quality of life
of both the patients and their caregivers. Dementia is
one of the main causes of early patient institutionaliza-
tion. It has been estimated that behavioral or neuropsy-
chiatric symptoms can manifest in 50% of all elderly
patients with dementia, and the frequency is moreover
higher among institutionalized individuals [4,8]. These
symptoms can show diverse presentations, in any evolu-
tive stage of the disease, and typically manifest in multi-
ple and oscillating forms [4].
At present, the most common cause of dementia is
Alzheimer’s disease (AD), of probable multifactorial
origin (genetic, environmental, toxic, etc.), followed by
vascular dementia (VD). The role of cerebrovascular
disease as a cause of dementia has been recognized for
over a century. We are now witnessing a redefinition
of the different forms of VD, with introduction of the
concept of vascular cognitive impairment, designed to
identify the early stages of a process hypothetically
amenable to preventive intervention and treatment.
Together with the classical vascular lesions (arterial
and lacunar infarctions), other types of cerebrovascular
lesions are becoming known such as leukoaraiosis or
incomplete infarctions, which contribute to the devel-
opment of intellectual impairment, and increased
insight is being gained to the clinical, neuropsychologi-
cal and radiological correlations involved. Behavioral
and psychological manifestations are increasingly
investigated and recognized as symptoms inherent to
VD [9,10]. Descriptive, analytical and interventional
epidemiological studies have underscored the relevance
of vascular factors as causal agents in dementia
[11,12]. Another important epidemiological aspect in
the field of vascular cognitive impairment refers to
cognitive impairment presenting in stroke patients. Up
to 30% of all patients with cerebral infarction develop
dementia in the three months following stroke - this
representing a 9-fold greater risk versus the controls
without stroke [12]. The repetition of stroke may trig-
ger dementia in some but not in all cases, and many
patients develop dementia without any apparent under-
lying clinical event. Furthermore, in many cases the
observed dementia corresponds to Alzheimer’sd i s e a s e
instead of vascular dementia. This point is important if
the vascular component of mixed dementia is amen-
able to preventive treatment.
Different strategies have been proposed for the pre-
vention of dementia, though none have yielded positive
results. Given the absence of quality clinical evidence
supporting their use, drug treatments (statins, hormone
replacement therapy or nonsteroidal antiinflammatory
drugs (NSAIDs)) are not advised for the primary
prevention of dementia [11]. This discouraging reality is
applicable to most dementias, since these are due to
Alzheimer’s disease, but it is possible to prevent the sec-
ond most common cause of dementia, i.e., vascular
dementia [1,3,4], which manifests as a consequence of
cerebrovascular disease. Regarding the primary preven-
tion of dementia, the PAPPS study [13] recommends
remaining socially and mentally active, physical activity,
and the observation of healthy living habits, with ade-
quate control of cardiovascular risk factors - particularly
correct blood pressure control.
Cardiovascular diseases are the main cause of death in
Spain, and are attributable particularly to cerebrovascu-
lar disorders and ischemic heart disease.
Arterial hypertension is a systemic condition that pre-
ferentially affects three body organs: the heart, kidneys
and brain. In contrast to the heart and kidneys, which
are systematically evaluated in clinical practice, brain
function is often neglected. Hypertension and dementia
are common disorders in the population over 65 years
of age. It has been estimated that 8% and 65% of these
individuals suffer dementia and hypertension, respec-
tively [14]. From this age onwards, the prevalence of
dementia increases exponentially, doubling every 5 years
and reaching 28.5% in people aged 90 years or older
(EURODEM study)[15,16].
The results of epidemiological studies in reference to
the association between these two disorders vary
depending on the methodology employed [17]. Thus,
while cross-sectional studies have reported contradictory
results [18-21], longitudinal surveys point to a positive
relationship between the presence of arterial hyperten-
sion in middle age and mild cognitive impairment 15-20
years later [22-24]. No such association has been
observed when arterial hypertension develops at an
older age [25-27]. Skoog et al. [28] found arterial hyper-
tension at 70 years of age to be greater in subjects who
developed dementia between 79 and 85 years of age.
However, during the years preceding the onset of
dementia, blood pressure decreases in comparison with
those subjects who do not develop dementia. Similar
findings have been published by Hanon [29] and
Verghese [30]. The correlation between blood pressure
and mild cognitive impairment is more complex than a
simple lineal relationship. Chronic hypertension
predisposes to mild cognitive impairment and the
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can be observed in the phase prior to the development
of diffuse cognitive impairment [28].
Likewise, no clear effect of antihypertensive treatment
has been observed in terms of the prevention of mild
cognitive impairment in hypertensive patients. A
Cochrane review [31] concludes that “There was no con-
vincing evidence in the reviewed trials to suggest that
lowered blood pressure prevents the development of
dementia or cognitive impairment in hypertensive
patients without manifest prior cerebrovascular disease”.
However, on considering the evidence of the cross-sec-
tional, longitudinal and observational studies together
with the evidence generated by the randomized clinical
trials (RCTs), moderately solid support is found of the
notion that hypertension in adult life - particularly when
not treated effectively - exerts a negative effect upon
cognition, and contributes to the development of
dementia and Alzheimer’s disease in old age [17,19,32].
There is less evidence from these studies that the same
negative effect upon cognition is present with hyperten-
sion at an older stage in life [19].
The relationship between cholesterol and mild cogni-
tive impairment is contradictory. There are several
cross-sectional PAPPS studies with differing results
[33,34]. There are also several longitudinal studies
reporting a positive association between total choles-
terol and mild cognitive impairment, while three
observe no association, and one reports a negative
association [35].
In reference to diabetes mellitus, a number of studies
have reported an association with the prevalence of
dementia, though others have found no such relation-
ship. Biessesls et al. [36], following an analysis of several
longitudinal studies, found the incidence of dementia to
increase between 50-100% in subjects with diabetes ver-
sus individuals without diabetes. Associations have also
been described with blood glucose [37] and glycosylated
hemoglobin. In this sense, for every 1% rise in HbA1c,
an increased risk of cognitive impairment or dementia
has been reported (OR 1.40: CI 1.08-1.83)[38].
Metabolic syndrome groups a series of cardiovascular
risk factors; as a result, an increased risk of target organ
damage could be expected in patients with this syn-
drome. However, few studies have evaluated the associa-
tion between metabolic syndrome and the development
of dementia or mild cognitive impairment. Some cross-
sectional [39] and longitudinal studies [40] have
described an association between metabolic syndrome
and cognitive impairment. Thus, while a certain rela-
tionship appears to exist, the risk of dementia in indivi-
duals with metabolic syndrome has not been firmly
established, and it is not clear whether such risk is
greater than the sum of its components [38].
Comorbidity among people over age 65 is common
and conditions the prognosis of other concomitant dis-
ease processes, with an acceleration of the possible com-
plications. Different methods are available for assessing
comorbidity. Charlson proposed a numerical scale using
a list of pathological conditions: the Charlson comorbid-
ity index [41,42]. This index was designed to classify
comorbidities for prognostic purposes, and posteriorly
has been used as a control of the influence which
comorbidity may exert in different situations. The
Charlson index has not been used in the analysis of car-
diovascular risk factors and cognitive impairment. Like-
wise, no study has been made of the association of
cardiovascular risk as estimated from the risk scales and
cognitive impairment in individuals over 65 years of age.
Less than one-half of all patients with Alzheimer’sd i s -
ease have been diagnosed, and of these subjects, approxi-
mately 25% are receiving some kind of treatment [43]. The
number of individuals with undiagnosed cognitive impair-
ment is therefore expected to be high, particularly in
groups with certain risk factors. One of the factors
explaining why many people with cognitive impairment
have not been diagnosed is related to the fact that we have
no cognitive impairment screening tool in the elderly
population sufficiently warranted by the scientific commu-
nity and the professionals who care for such patients.
Based on a neuropsychological battery especially
adapted for the study of elderly people, we will carry
out a study of cognitive performance in people over 65
years of age in Salamanca (Spain), with special emphasis
on the identification of early symptoms of cognitive
impairment, with the purpose of detecting mild cogni-
tive impairment and of studying the relationships
between this clinical situation and cardiovascular risk
factors.
The following objectives have been established:
1. To study the cognitive performance of people over
65 years of age in Salamanca, with a view to estimat-
ing the prevalence of the different manifestations of
cognitive impairment and its severity.
2. To analyze the association of cardiovascular risk
factors (diabetes, arterial hypertension, dyslipidemia
and metabolic syndrome) in patients over age 65
with mild cognitive impairment.
3. To use the Mini - Mental State Examination
(MMSE) and the 7 Minute Screen test as screening
tools for cognitive impairment in the elderly popula-
tion under study.
Methods/Design
Design and study population
A longitudinal study will be carried out, since we will
be starting from a reference population of 327 people
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(Spain) and who participated in the cross-sectional
study entitled “Sociosanitary needs of people over 65
years of age in the city of Salamanca”,f i n a n c e db yt h e
regional health authorities (SOCIO673/01/08). Rando-
mized sampling is contemplated, stratifying for health-
care area.
Power analysis
The population universe was the city of Salamanca, with
a total of 172,375 people. A 19.74% out of them
(34,020) was 65 years old or more, while in rural empla-
cement of the region the population older than 65 years
old was a 30.25%. It was estimated that it would be a
16% at least.
Taking an alpha risk of 0.05, a power of 20% and esti-
mating the sum of prevalence of mild cognitive impair-
ment plus dementia around a 16%, with a mistake of
4%, and taking into consideration the current population
of 65 years old or older, it would be needed 320 partici-
pants. Considering up to a 50% of loss for no response
and according to similar studies, sample size was 480
participants.
In this first study the population structure was taken
into account as established from the individual health-
care cards database of the Primary Care management
authorities of Salamanca, with sampling stratified
according to healthcare centers. The mentioned study
was carried out through home interviews.
Measurements
The principal study measurements are the following:
a) Sociodemographic variables: age, sex, educational
level, marital status, family unit.
b) Anthropometric variables and physical evaluation:
body weight, height, waist circumference, blood pres-
sure, heart rate, physical activity, lipid profile, blood
glucose.
c) Vascular risk factors: smoking, hypertension, dia-
betes mellitus, dyslipidemia, obesity, alcohol intake.
d) Cardiovascular disease: stroke, heart disease, neuro-
pathy, retinopathy.
e) Drug use (antihypertensive, antidiabetic, lipid-low-
ering and antiplatelet drugs, psychoactive medication).
f) Comorbidity.
g) Functional grade will be evaluated in reference to
daily life activities (both basic and instrumental), and
data from an informant will be obtained.
h) Neuropsychological assessment: assessment of the
premorbid situation, attention-concentration, speech,
logical memory, auditory-verbal learning, visioconstruc-
tion memory, visual memory, executive function. Fol-
lowing evaluation, the impairment phases will be
classified, ranging from normality to the most severe
phases of dementia.
Measurement instruments
1. Anthropometric measurements
a) Height: the mean of two measurements using a wall
meter (Seca 222), with the patient barefoot and in the
erect standing position, and measuring to the nearest
millimeter. Body mass index: weight (kg)/height (m)
2.
b) Waist circumference: the mean of three measure-
ments, using a flexible measuring tape at waist level (at
the midpoint between the last rib and the iliac crest),
parallel to the floor, and measuring after inspiration.
c) Weight: the mean of two measurements using a
homologated and easily calibrated scale (Seca 770) with
the patient barefoot and lightly clothed. The readings
will be rounded to 100 grams.
d) Clinical blood pressure (OMROM M-7): three mea-
surements of systolic blood pressure (SBP) and diastolic
blood pressure (DBP) will be made, calculating the
mean of the last two readings, and using a validated
sphygmomanometer (OMRON M7), following the
recommendations of the European Society of Hyperten-
sion. Pulse pressure (PP) will be estimated with the
mean values of the second and third measurements.
e) Physical activity: Physical activity will be estimated
by the 7-day Physical Activity Recall (PAR)[44]. The
PAR is a general measure of physical activity, which has
been recognized as a valid and reliable tool in recent
years, and is widely used in epidemiological, clinical and
behavioral change studies. It consists of a semi-struc-
tured interview (10-15 minutes) in which the partici-
pants provide an estimate of the number of hours
dedicated to physical or occupational activities requiring
at least a moderate effort in the past 7 days. The cate-
gories collected are: moderate, vigorous, and very vigor-
ous physical activity. The dose of physical exercise will
be estimated in METs/hour/week, and active persons
will be taken to be those doing at least 30 minutes of
moderate activity, 5 days a week, or at least 20 minutes
of vigorous activity, 3 days a week. Persons not reaching
this level of physical activity are regarded as sedentary.
2. Cardiovascular risk and stroke risk scales
Estimated risk at 10 years will be calculated according to
the Framingham risk scales for stroke and global cardio-
vascular morbidity-mortality [22].
3. Measurement of comorbidity
The disorders established by Charlson in the original
article published in 1987 [41] are: myocardial infarction;
congestive heart failure; arterial hypertension; peripheral
vascular disease; cerebrovascular disease; dementia;
chronic pulmonary disease; connective tissue disease;
peptic ulcer; mild, moderate or severe liver disease; dia-
betes with or without organ damage; hemiplegia; leuke-
mia; lymphoma; solid tumor with metastasis; AIDS; and
moderate or severe kidney disease. After establishing
patient comorbidity, each entity will be scored in a table
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comorbidity index (CCI). In order to calculate the age-
adjusted Charlson comorbidity index (ACCI), we add
one point to the CCI for each decade above 50 years of
age. The values obtained will be grouped into four cate-
gories: 1-2, 3-4, 5-7 or ≥ 8.
4. Need for help in daily life activities
Use will be made of the Barthel index [45] for the eva-
luation of basic daily life activities and of the Lawton
and Brody index [46] for the evaluation of instrumental
daily life activities. The short version informant test
(IQCODE) will be applied [47,48]. This is a question-
n a i r et ob ec o m p l e t e db yar e l a t i v eo rp e r s o nc l o s et o
the patient. Following a series of short instructions, and
in very little time, the informant is asked to recall how
the patient was 10 years ago, and how he or she has
changed since then, based on a 5-point Likert scale. The
short version comprises 17 questions.
5. Neuropsychological assessment protocol
a) Cognitive screening: The Folstein Mini-Mental Test,
MMSE [49], and the 7 Minute Screen [50,51], are cogni-
tive screening tests that explore a number of cognitive
areas which are particularly affected in an early stage in
Alzheimer-type dementia and in other dementias.
b) Evaluation of the premorbid situation: The word
accentuation test [52] allows us to quickly estimate the
premorbid intellectual level of the subject. It consists of
30 infrequent words that are presented to the subject
(without accentuations), and which he or she must read
correctly (phonetic accent).
c) Attention-concentration: This is a digit subtest to
the right and reverse [53]. It assesses attention, as well
as storage and immediate recall of a series of numbers.
d) Speech: The Boston vocabulary test [54] explores
denomination capacity based on the visual confrontation
of 60 images.
Semantic - phonetic generation [55], comprising two
subtests. The first, names of animals, evaluates semantic
verbal fluency. The subject is asked to name animals as
q u i c k l ya sp o s s i b l ea n di no n em i n u t e .T h es c o r ei st h e
number of words evoked by the patient. The second
subtest is words that begin with the letter “p”, and evalu-
ates phonologic verbal fluency. The subject is asked to
name words that begin with the letter “p”.T h es c o r ei s
the number of words evoked by the patient in a period
of one minute.
e) Logical memory: Babcock story [56], immediate
and delayed. The explorer reads a story to the subject,
who in turn is required to recall it immediately,
thereby assessing retention memory and immediate
recall corresponding to logical structured verbal mate-
rial. After non-mnesic interference (approximately 15
minutes), the subject is instructed to repeat what he
or she remembers about the story (delayed logical
verbal memory). The story consists of 21 information
units.
f) Visuoconstruction memory: Rey complex figure test
[57]. This test involves two phases: copy and memory.
Memory reproduction informs us of the visual memory
of the subject, as well as of his or her visuoconstruction
capacity. Subject performance is evaluated according to
the number of correct units conforming the complete
figure (the maximum score being 36), the type of execu-
tion of the subject, and the time (in seconds) used to
construct the figure.
h) Visual memory: The Benton visual retention test
will be used [58]. We will apply form C, Administration
A. This involves presentation of each of the sheets, dur-
ing 10 seconds, followed by immediate memory repro-
duction or recall by the subject. This test evaluates the
visuospatial perception of the subject, as well as visual
memory, visuoconstruction skills and visual conceptuali-
zation. Subject performance is evaluated according to
the number of correct reproductions (the maximum
score being 10) and error assessment (taking into
account the specific type of error made by the subject:
omission, distortion, displacement, perseverance, rota-
tion, size and whether located to left or right).
i) Executive function: Abbreviated Frontal Assessment
Battery (FAB)[59]. This test evaluates frontal lobe func-
tions based on 6 tasks: similarities (formation of con-
cepts), verbal fluency (mental flexibility), motor series
(programming), interference (execution of conflictive
instructions), control (response inhibition) and auton-
omy (environmental independence). The action-verb flu-
ency test [60] in turn requires the subject to evoke the
largest possible number of words designating an action
(verbs), in 60 seconds. The score in this task is the total
number of words correctly evoked within the limited
time interval.
g) Visuoconstruction skills: the Rey complex figure
test [57]. Copying of the figure evaluates subject visual
perception, practical-constructive skills, visuospatial ana-
lytical capacity, and right-left orientation. The assess-
ment is the same as commented above in the memory
figure reproduction phase.
h) Cognitive impairment: classification of the severity
of cognitive impairment in 7 global stages ranging from
normal to severe impairment, based on the Global Dete-
rioration Scale (GDS) [61].
Procedure
All participants will be informed of the purpose of the
study by telephone and conventional mail, and will be
asked to give written informed consent to participation.
Once consent has been obtained, all subjects will receive
a card stating the place, date and exact time of the eva-
l u a t i o n .O n ed a yb e f o r et h es t u d yt h es u b j e c t sw i l lb e
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tion will be carried out in the Faculty of Psychology of
the University of Salamanca, in Room 19 (specifically
used for neuropsychological tests).
The sessions will be individualized, and the procedure
will be the same for all participants, using the aforemen-
tioned measurement instruments.
The estimated duration of the evaluation is 120 min-
utes, with two resting intervals of about 15 minutes
each.
The clinical and laboratory test data can be collected
on occasion of a second interview to be arranged with
the participants and/or relatives.
Statistical analysis
A descriptive analysis of the data will be made, estab-
lishing comparisons with the baseline evaluation of the
previous study. Posteriorly, an analysis will be made of
the qualitative variables using the chi-squared test, and
the qualitative and quantitative variables will be analyzed
using the Student t-test and analysis of variance
(ANOVA), depending on whether two or more cate-
gories are involved. An analysis will be made of the cor-
relations of the quantitative variables, together with
multiple regression analysis to identify the variables
associated with cognitive impairment diagnosed by the
neuropsychological tests.
Likewise, an evaluation will be made of the sensitivity,
specificity and predictive values of the tests employed in
screening for cognitive impairment, using the neuropsy-
chological evaluation made as gold standard.
Lastly, we will analyze the evolution of the different
parameters between the two evaluations made, attempt-
ing to identify those variables with greater predictive
capacity in reference to the evolution of cognitive
impairment.
The information will be analyzed according to the
place of residency, age and sex of the patient, the family
situation and patient cognitive impairment, risk factors
and comorbidity index.
Data input will be made using the Teleform system,
with a questionnaire previously designed for the project,
and exporting the data to the SPSS statistical package
for posterior analysis.
Ethical and legal issues
In order to guarantee data confidentiality, all the electro-
nic and paper copies of the protocol, signed informed
consent documents and results of the tests made in each
of the patients will be kept locked in a safe place, and
only the study investigators will have access to the data
on the subjects who agree to participate in the study.
The protocol was approved (August 10, 2010) by the
Clinical Research Ethics Committee of Salamanca
University Hospital (Spain), and complies with Spanish
data protection law 15/1999 and its recently developed
specifications (Royal Decree (RD) 1720/2007). Knowl-
edge and agreement to cooperate has been established
with the implicated services, signed by the legal repre-
sentative of the center.
Methodological limitations
The main limitation is sample loss inherent to studies of
this kind, since the voluntary nature of participation and
the population characteristics referred to age, etc.,
implies a certain loss of subjects versus the initially esti-
mated sample size. The main causes underlying such
losses are death and increased physical or mental
impairment of the participants.
Discussion
There are studies in which a link has been established
between cardiovascular risk factors and the develop-
ment of dementia. However, few studies have related
mild cognitive impairment to cardiovascular risk. We
hope that this study will afford objective information
o nt h er e p r e s e n t a t i v ep r e v a l e n c eo fm i l dc o g n i t i v e
impairment in the population over 65 years of age in
Salamanca.
We will conduct an analysis of the cardiovascular risk
factors in the selected sample, allowing us to establish
the possible correlation between certain cardiovascular
risk markers and mild cognitive impairment. If found,
such a correlation would be very useful for future stu-
dies designed to allow a certain prevention of such
impairment, based on control of the cardiovascular risk
factors.
The results obtained moreover will allow us to assess
the predictive capacity in detecting cognitive impairment
from the applied screening tests (MMSE and 7 Minute
Screen), since their results will be contrasted with those
of the detailed neuropsychological explorations. The
importance of the early detection of cognitive impair-
ment should be stressed, since it will allow the start of
adequate treatment and thus can contribute to improve
patient quality of life.
Lastly, we wish to point out that since a randomized
population-based sample from the city of Salamanca is
involved, the information obtained may be of increased
representativeness - particularly considering that many
studies suffer bias due to the lack of purely randomized
criteria in selecting the participants.
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